What it’s like to be infected with coronavirus

heart failure treatment :: Article Creator

ECU Health Receives National Heart Treatment Award

GREENVILLE, N.C. (WNCT) — The American Heart Association and American Stroke Association are honoring ECU Health on a national level.

The 'Get with the Guidelines' Achievement Awards honors excellence in work treating stroke, diabetes, cardiac arrest, heart attack, and heart failure. The award recognizes ECU Health's commitment to following up to date, research based guidelines for treatment which leads to more lives saved and shorter recovery times.

"They're really real conditions that take such a toll on the health and well-being of eastern North Carolina. For our facilities across a very challenged environment to have a commitment to be able to deliver evidence based care locally to those communities is what this really is all about." said Dr. Niti Singh Armistead, Chief Quality Officer of ECU Health.

All nine ECU Health hospitals received the national recognition.

For the latest news, weather, sports, and streaming video, head to WNCT.

View comments

Buy Rating Affirmed For Lexicon Pharmaceuticals On Promising INPEFA Heart Failure Treatment Data

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $10.00.

Joseph Pantginis has given his Buy rating due to a combination of factors, most notably the promising data surrounding Lexicon Pharmaceuticals' INPEFA treatment as detailed in a recent post-hoc analysis of their Phase 3 SCORED trial. This analysis, presented at ESC '24, indicated that INPEFA is effective in improving heart failure (HF) outcomes, particularly in patients with a longer history of diabetes. Such findings are significant as they suggest that INPEFA not only has a broad therapeutic impact but also offers increased benefits to a demographic at high risk for cardiovascular complications.

Moreover, the data show that INPEFA reduces the overall risk of major adverse cardiovascular events (MACE) and HF events, with an amplified benefit correlating with the duration of the patient's diabetes diagnosis. The potential of INPEFA to deliver enhanced outcomes in HF patients regardless of their diabetes duration presents a strong case for its differentiation in the HF treatment market. Pantginis's rating reflects the potential market opportunity for Lexicon Pharmaceuticals, as INPEFA could meet a critical need for patients predisposed to cardiovascular disease, particularly those with long-standing diabetes.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Lexicon Pharmaceuticals (LXRX) Company Description:

Lexicon Pharmaceuticals, Inc. Engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

All Types Of Heart Failure May Benefit From Treatment With MRAs

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure hospitalisation in patients with heart failure and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to new research.

The latest study, presented by Professor Pardeep Jhund at the ESC (European Society of Cardiology) Congress 2024 and simultaneously published in The Lancet, showed, for the first time, that treatment with MRAs can benefit patients with all types of heart failure and should be prescribed in suitable patients going forward.

An illustration of a heart on a blue background

Previously there was strong evidence that MRAs could improve cardiovascular outcomes in patients with heart failure and reduced ejection fraction (HFrEF), however the benefits for patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) were less clear. To answer these questions, this study examined the effects of MRAs using data from four trials across both types of heart failure.

This was a pre-specified, individual patient-level meta-analysis of four placebo-controlled trials: RALES (spironolactone) and EMPHASIS-HF (eplerenone), which enrolled HFrEF patients, and TOPCAT (spironolactone) and FINEARTS-HF (finerenone), which enrolled HFmrEF/HFpEF patients. The effect of MRAs was estimated for the outcomes of cardiovascular death or HF hospitalisation, components of this composite, total HF hospitalisations (with and without cardiovascular deaths) and all-cause death. An interaction between trials and treatment was tested to examine the heterogeneity of effect in the populations.

In 13,846 patients, MRAs reduced the risk of cardiovascular death or HF hospitalisation by 23%. There was also a significant interaction by trials and treatment due to the greater efficacy in HFrEF (34% reduction) compared with HFmrEF/HFpEF (13% reduction). The effects were consistent across all subgroups in the HFrEF and HFmrEF/HFpEF trials.

Significant reductions in HF hospitalisation were observed in the HFrEF trials (37% reduction) and the HFmrEF/HFpEF trials (18% reduction) The same pattern was observed for total HF hospitalisations with or without cardiovascular death. Cardiovascular death was reduced in the HFrEF trials (by 28%) but the reduction (8%) in the HFmrEF/HFpEF trials did not reach statistical significance.

The risk of hyperkalaemia was doubled with an MRA compared with placebo, but the incidence of serious hyperkalaemia (defined as a laboratory potassium >6.0 mmol/L) was low (2.9% vs. 1.4%). The risk of hypokalaemia (potassium <3.5 mmol/L) was halved (7% vs. 14%).

Professor Jhund, Professor of Cardiology and Epidemiology at the University of Glasgow's School of Cardiovascular & Metabolic Health, said: "This analysis confirms the benefits of MRAs in patients with HF, across the spectrum of ejection fractions. Our findings indicate that treatment with an MRA may be considered in all patients with HF without a contraindication."

The study, 'MRAs in heart failure - An individual patient data meta-analysis of randomised trial' is published in The Lancet.

Enquiries: ali.Howard@glasgow.Ac.Uk or elizabeth.Mcmeekin@glasgow.Ac.Uk

First published: 1 September 2024

Ebola Virus Disease